Anticancer Drugs Durvalumab Oncology Pharmacology Physiotherapy

Durvalumab (Warnings-25)

In this article we will discuss Durvalumab (Warnings-25)

In this article, we will discuss Durvalumab (Warnings-25). So, let’s get started.

Immune-Mediated Nephritis with Renal Dysfunction: Durvalumab can cause immune-mediated nephritis. Immune-mediated nephritis occurred in 0.5% (10/1889) of patients receiving Durvalumab, including Grade 3 (<0.1%) adverse reactions. Events resolved in 5 of the 10 patients and resulted in permanent discontinuation in 3 patients. Systemic corticosteroids were required in all patients with immune-mediated nephritis.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.